174 related articles for article (PubMed ID: 24906398)
1. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Tsuda M; Ishiguro H; Yano I; Toi M
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
[No Abstract] [Full Text] [Related]
2. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Adhikaree J; Newby Y; Sundar S
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
[No Abstract] [Full Text] [Related]
3. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
[TBL] [Abstract][Full Text] [Related]
4. Response.
Glezerman IG; Hu MI; Jain RK
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906399
[No Abstract] [Full Text] [Related]
5. Treatment of bisphosphonate-resistant hypercalcemia of malignancy with calcitonin.
Dawson C; Todd AM; Walton A
J Palliat Med; 2014 Oct; 17(10):1084. PubMed ID: 25265187
[No Abstract] [Full Text] [Related]
6. NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.
Jilani A; Garrett Z; Sutcliffe F; Stevens A
Lancet Oncol; 2012 Dec; 13(12):1194-5. PubMed ID: 23323278
[No Abstract] [Full Text] [Related]
7. [Management of bone metastases].
Nagykálnai T; Landherr L
Orv Hetil; 2014 Feb; 155(6):217-25. PubMed ID: 24486845
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
9. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
Boikos SA; Hammers HJ
J Clin Oncol; 2012 Oct; 30(29):e299. PubMed ID: 22949145
[No Abstract] [Full Text] [Related]
10. Denosumab: a new agent in the management of hypercalcemia of malignancy.
Thosani S; Hu MI
Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
[TBL] [Abstract][Full Text] [Related]
11. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
[TBL] [Abstract][Full Text] [Related]
12. The pharmacological management of skeletal-related events from metastatic tumors.
Hitron A; Adams V
Orthopedics; 2009 Mar; 32(3):188. PubMed ID: 19309055
[TBL] [Abstract][Full Text] [Related]
13. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
14. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
15. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
16. Denosumab and bone metastases. No better than a bisphosphonate.
Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
[TBL] [Abstract][Full Text] [Related]
17. Re: Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of three pivotal, randomised, phase 3 trials.
Araki K; Ito Y; Takahashi S
Eur J Cancer; 2013 Jun; 49(9):2264-5. PubMed ID: 23541567
[No Abstract] [Full Text] [Related]
18. Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Lin PH; Chiu CF; Lu YS
Ann Oncol; 2011 May; 22(5):1244-1246. PubMed ID: 21460375
[No Abstract] [Full Text] [Related]
19. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
Kohno N
Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
[TBL] [Abstract][Full Text] [Related]
20. [Progress in diagnosis and therapy: Hypercalcemia due to multiple myeloma and wide-spread neoplastic bone metastasis].
Abe M
Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):675-80. PubMed ID: 17506303
[No Abstract] [Full Text] [Related]
[Next] [New Search]